Competitive Advantage / VALUE PROPOSITION
World-Class Pipeline
Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs
Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals. On 17th of January 2023 FSD Pharma has submitted its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation
FSD201: Proprietary ultra-micro PEA (palmitoylethanolamide) compound, solid safety profile in humans, Phase-2 clinical trials for inflammatory disease is currently ongoing
Lucid-Psych: Novel pathway (unique MOA) to treat Major Depressive Disorder, Phase 1 clinical trial targeted for end of first quarter of 2023
IP Estate: FSD Pharma has rights to patent families licensed on an exclusive basis
Elite Team
FSD Pharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of
the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).
FSD Pharma has a world class team working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.
FSD Pharma team includes 2
Julia Levy Award recipients, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)
Strong Cash Position
Cash enough to carry operations (including 3 planned clinical trials)
No dilution on horizon for shareholders
Solid Cap Table / Insider Ownership
Only 38.1 million shares issued
Share repurchase plan ongoing, approximately 2 million shares returned to treasury in 2022
Co-founders, directors and other insiders frequently buying shares since start of 2022 and continue to accumulate shares. This can be verified by checking the SEDI filings
*Data current as of October 03, 2022
A strong balance sheet represented by no debt and enough of working capital including taking the 3 different molecules through clinical trials
Developing novel myelin repairing compounds for the treatment of neurodegenerative and neuropsychiatric diseases
Two lead candidatesvto improve patient outcomes and address large populations ($23B multiple sclerosis market and $238B mental health market)
Lead compound, FSD201, a proprietary ultra micro PEA compound, has shown effective anti-inflammatory properties and a favorable safety profile proving potential viability for a range of conditions
Well capitalized to pursue acquisitions that advance our mission to deliver today’s most innovative treatments for Total Brain Health
On 17th of January FSD Pharma has submitted its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation. This trial will be First In Class for its Multiple Sclerosis drug candidate
Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-Psych by the end of first quarter of 2023
Advancement of FSD-201 for phase-2 trials for chronic widespread musculoskeletal nociplastic pain associated with Idiopathic Mast Cell Activation Syndrome (Disorder) which is currently ongoing.
World class and experienced team of scientists, researchers and doctors from world class institutions or organizations
